XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2023
Feb. 28, 2019
Sep. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Disaggregation Of Revenue [Line Items]                
Revenue from collaboration agreement     $ 46,435,000 $ 37,919,000   $ 131,498,000 $ 124,492,000  
Deferred revenue     84,637,000     84,637,000   $ 93,423,000
Immune Medicine Service Revenue                
Disaggregation Of Revenue [Line Items]                
Revenue from collaboration agreement     3,500,000 8,000,000   10,000,000 34,700,000  
Medicare Reimbursements                
Disaggregation Of Revenue [Line Items]                
Revenue from collaboration agreement     1,500,000 $ 1,900,000   4,300,000 4,600,000  
Medicare Reimbursements | Immune Medicine Service Revenue                
Disaggregation Of Revenue [Line Items]                
Revenue from collaboration agreement     1,000,000     1,100,000 400,000  
Medicare Reimbursements | MRD Service Revenue                
Disaggregation Of Revenue [Line Items]                
Revenue from collaboration agreement             $ 4,200,000  
MRD Development Agreements | Maximum                
Disaggregation Of Revenue [Line Items]                
Additional milestone payment receivable     418,500,000     418,500,000    
Genentech Collaboration Agreement                
Disaggregation Of Revenue [Line Items]                
Revenue from collaboration agreement         $ 7,700,000      
Non-refundable upfront payments received   $ 300,000,000.0       300,000,000.0    
Expected revenue through milestone payments     1,800,000,000     $ 1,800,000,000    
Additional transaction price of regulatory milestone $ 10,000,000              
Genentech Collaboration Agreement | Regulatory Milestones                
Disaggregation Of Revenue [Line Items]                
Additional transaction price of regulatory milestone $ 10,000,000.0              
Genentech Collaboration Agreement | Maximum                
Disaggregation Of Revenue [Line Items]                
Revenue recognition expected period           9 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones                
Disaggregation Of Revenue [Line Items]                
Expected revenue through milestone payments     65,000,000.0     $ 65,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones                
Disaggregation Of Revenue [Line Items]                
Expected revenue through milestone payments     300,000,000.0     300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones                
Disaggregation Of Revenue [Line Items]                
Expected revenue through milestone payments     $ 1,430,000,000     $ 1,430,000,000